Vitamin D Inadequacy is Associated With Incidence of Type 2 Diabetes
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Emerging evidence suggests that vitamin D [25-hydroxyvitamin D; 25(OH)D] may play a role in the etiology of type 2 diabetes. Vitamin D levels are lower in those with type 2 diabetes and impaired glucose tolerance (IGT) compared with those with normal glucose tolerance (NGT). In addition, a few prospective studies have shown a significant inverse association of baseline serum 25(OH)D with incident diabetes. To date, however, the exact mechanisms through which vitamin D affects diabetes risk are not yet fully known, particularly whether vitamin D plays a role in insulin resistance (IR) and/or b-cell dysfunction, the main pathophysiological disorders underlying type 2 diabetes. So, the investigators plan to examine the prospective associations of baseline vitamin D [25-hydroxyvitamin D; 25(OH)D] with insulin resistance (IR), b-cell function, and glucose homeostasis in subjects at risk for type 2 diabetes.
| Condition |
|---|
|
Type 2 Diabetes |
| Study Type: | Observational |
| Study Design: | Observational Model: Cohort Time Perspective: Prospective |
| Official Title: | Vitamin D Inadequacy is Associated With Incidence of Type 2 Diabetes |
- Incidence of diabetes [ Time Frame: 5 years ] [ Designated as safety issue: No ]Incidence of diabetes defined by American Diabetes Association criteria
- Pancreatic beta cell function [ Time Frame: 5 years ] [ Designated as safety issue: No ]Pancreatic beta cell function assessed by homeostasis model
- Insulin resistance [ Time Frame: 5 years ] [ Designated as safety issue: No ]Insulin resistance assessed by homeostasis model
Biospecimen Retention: None Retained
Blood sample was collected at the baseline.
| Enrollment: | 1500 |
| Study Start Date: | January 2007 |
| Study Completion Date: | October 2012 |
| Primary Completion Date: | October 2012 (Final data collection date for primary outcome measure) |
| Groups/Cohorts |
|---|
| Diabetes high risk group |
Eligibility| Ages Eligible for Study: | 30 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
| Sampling Method: | Non-Probability Sample |
Study participants, aged over 30 years, are recruited from Korea, between January 2006 and December 2011. Participants are at high risk for type 2 diabetes, as they are recruited on the basis of the presence of one or more risk factors for diabetes, including obesity, hypertension, dislipidemia, and a family history of diabetes. Participants are contacted every 6 month after the baseline visit to update contact information and collect data on major health events. Participants are invited to return to the clinic examination centers after 3 years for follow-up assessments.
Inclusion Criteria:
one or more risk factors for diabetes, including:
- obesity
- hypertension
- dislipidemia
- a family history of diabetes
Exclusion Criteria:
- previous diagnosed diabetes
- vitamin D supplement.
Contacts and Locations| Korea, Republic of | |
| Seoul National University Bundang Hospital | |
| Seongnam, Korea, Republic of, 463-707 | |
| Principal Investigator: | Soo Lim, MD, PHD | Seoul National University Bundang Hospital |
More Information
No publications provided by Seoul National University Bundang Hospital
Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Soo Lim, Principal Investigator, Seoul National University Bundang Hospital |
| ClinicalTrials.gov Identifier: | NCT01508481 History of Changes |
| Other Study ID Numbers: | VitaminD_T2DM |
| Study First Received: | January 5, 2012 |
| Last Updated: | October 5, 2012 |
| Health Authority: | South Korea: Institutional Review Board |
Keywords provided by Seoul National University Bundang Hospital:
|
Vitamin D Diabetes pancreas beta cell function insulin resistance Deficiency of Vitamin D3 |
Additional relevant MeSH terms:
|
Diabetes Mellitus Diabetes Mellitus, Type 2 Glucose Metabolism Disorders Metabolic Diseases Endocrine System Diseases Vitamin D Ergocalciferols |
Vitamins Bone Density Conservation Agents Physiological Effects of Drugs Pharmacologic Actions Micronutrients Growth Substances |
ClinicalTrials.gov processed this record on May 16, 2013